Vericel Corp Files 8-K for Regulation FD Disclosure

Ticker: VCEL · Form: 8-K · Filed: Apr 14, 2025 · CIK: 887359

Sentiment: neutral

Topics: regulation-fd, disclosure

TL;DR

Vericel filed an 8-K for a Reg FD disclosure, no new material info.

AI Summary

Vericel Corporation filed an 8-K on April 14, 2025, reporting a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events beyond the disclosure itself. The company, formerly known as Aastrom Biosciences Inc., is based in Cambridge, MA.

Why It Matters

This filing indicates Vericel Corporation is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not appear to contain any new material negative or positive information about the company's operations or financial health.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing?

The purpose of this 8-K filing is to report a Regulation FD Disclosure by Vericel Corporation.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is April 14, 2025.

What is Vericel Corporation's former company name?

Vericel Corporation's former company name was Aastrom Biosciences Inc.

Where are Vericel Corporation's principal executive offices located?

Vericel Corporation's principal executive offices are located at 64 Sidney Street, Cambridge, MA 02139.

What is the SIC code for Vericel Corporation?

The Standard Industrial Classification (SIC) code for Vericel Corporation is 2836, for Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 regarding Vericel Corp (VCEL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing